Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

• Status: Recruiting
• Trial end date: 2025-03-26
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this open label,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of Chidamide combination with lenalidomide for relapsed or refractory peripheral T-cell lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Lenalidomide

Criteria

Inclusion Criteria:

• peripheral T cell lymphoma (PTCL);

• no remission or relapse after at least one previous systemic treatment；

• at least one assessable lesion；

• 18-75 years;

• ECOG PS 0-2;

• proper functioning of the major organs;

• expected survival time ≥3 months.

Exclusion Criteria:

• previous received treatment of HDAC inhibitor or lenalidomide;

• central nervous system (CNS) involvement;

• serious heart problems;

• known allergies to experimental drug ingredients;

• diagnosed with or receiving treatment for a malignancy other than lymphoma;

• uncontrolled active infection, with the exception of tumor-related b-symptom fever;

• unable or unwilling to receive antithrombotic therapy;

• history of deep vein thrombosis (DVT) or pulmonary embolism (PE) in the past 12 months;